Clinical Flashcards
cancers effective screening from Pap
squamous cell carcinoma
not good at preventing adenocarcinoma
conventional Pap
plastic spatula scraping cervix
liquid based
same technique but placed in liquid in vial
inflammation, blood can be removed prior to slide prep
additional testing for HPV, chlamydia, gonorrhea
image analysis systems
computer analyzes slide and picks out most atypical cells
pathologist reviews slide
specimen adequacy
presence or absence of transformation zone
general categorization
negative for lesion or malignancy or an abnormality present
epithelial cell abnormality
squamous cell
atypical of undetermined significance, low grade intraepithelial, high grade, or carcinoma
glandular cell abnormality
atypical of undetermined significance, cervical adenocarcinoma in situ, or adenocarcinoma of endocervical or endometrial origin
near 100% sensitivity
liquid based plus testing for high risk HPV
paradox of Pap
less efficient in detecting invasive cancer than in finding preinvasive disease
most important reason for failure of Pap
women fail to get screened
age of Pap recommendation
21
reflex testing
21-30 if ASCUS then test for HPV
cotesting
over 30 test together (HPV and pap)
cytology interval
3 years
cotesting interval
5 years
most common drugs consumed during pregnancy
analgesics antacids antibiotics antiemetics sedatives antihistamines diuretics ethanol iron vitamins
DES use and teratogenicity
used for pregnancy wastage
caused clear cell vaginal adenocarcinoma
thalidomide use and teratogenicity
insomnia
caused phocomelia, facial palsy
bendectin use and teratogenicity
anti-emetic
caused presumed malformations
results of fetal alcohol syndrome
decrease in uterine growth, psychomotor dysfunction
craniofacial abnormalities
embryogenesis
3-8 weeks
fetogenesis
affects gonadal development or nervous system
altered distribution in pregnancy
increased plasma volume and TBW late in pregnancy
decrease in albumin leads to increased free fraction
biotransformation in pregnancy
maternal liver
fetal liver
placenta
excretion changes in pregnancy
GFR increase
renal excretion of drugs
drugs cannot enter fetus
insulin and heparins
FDA category A
fail to demonstrate risk in first trimester
FDA category B
not demonstrated fetal risk in animals, not confirmed in humans
FDA category C
animals adverse effect on fetus no controls in women
only if beneficial to fetus
FDA category D
positive evidence of human fetal risk but benefits for pregnancy acceptable despite risk
FDA category X
fetal risk and risk during pregnant women outweighs benefits
contraindicated
adverse of androgen
virilization
adverse of antineoplastics
multiple congenital defects
adverse of systemic corticosteroids in high dosage
cleft lip/palate
adverse of DES
vaginal adenosis and adenocarcinoma in daughters
adverse of tetracyclines
yellow discoloration of teeth, inhibition of bone growth
adverse of warfarin
multiple congentital defects, skeletal, and CNS defects
adverse of systemic retinoids
CNS, craniofacial, cardiovascular
adverse chloroquine
deafness
adverse lithium
cardiovascular defects
adverse phenytoin
congenital defects
other drugs to avoid
co-trimoxazole, rifampicin, sulfonyluras, trimethoprim
adverse aspirin
kernicterus, hemorrhage
adverse aminoglycoside
eighth nerve damage
antithyroid drugs adverse
goiter and hypothyroidism
asplenia with methimazole
adverse benzodiazepines
floppy infant syndrome
adverse chloramphenicol
periperhal vascualr collapse
adverse oral anticoagulants
fetal or retroplacental hemorrhage, microcephaly
adverse sulfonylurea
hypoglycemia
adverse sulfonamides
kernicterus
adverse tetracyclines
teeth
adverse thiazide diuretics
thrombocytopenia
adverse chloramphenicol
grey baby
adverse streptomycin
ototoxicity
treatment of UTI in pregnancy
nitrofurantion, penicillins, trimeth/sulfa
treatment bacterial vaginosis
metronidazole
treatment candidiasis
azoles
treatment acute bacterial sinsitis
trimeth/sulfa, penicillins, azithromycin
treat nausea
promethazine
anemia in pregnancy
iron of folic acid
treat maternal hyperthyroidism
carbimazole, methimazole or propylthiouracil (concern of hepatic failure)
avoid breast feeding
treat pre-existing insulin dependent DM
change from oral hypoglycemics to human insulin
likely safe diabetes drugs
metformin and glyburide
treat pre-eclampsia
methyldopa
hydralazine
labetalol
drugs to avoid for HTN in pregnancy
diuretics and BB without alpha blocking activity
ACEi and ARB
treat anticoagulation
heparin or LMW heparin until 2-3 weeks before delivery
teat epilepsy
slight teratogenicity with phenytoin monitor plasma (decrease albumin) and supplement with folic acid before conception and until end of 1st trimester
asthma treatment
beta sympathomimetics for acute exacerbations
inhaled corticosteroids
systemic corticosteroids for severe
leukotriene inhibitors third line
nausea and vomiting treatment
only if severe
smaller meals, ginger, pridoxine
use promethazine or prochlorperazine
ondansetron appears safe
hyperemesis gravidarium
requiring hospitalization due to dehydration
due to elevated E/P/hCG
treat depression
abrupt withdrawal dangerous
defects paroxetine
cardiac defects, ASD/VSD
tobacco in pregnancy
increase fetal death or loss, increase premature birth and decrease weight
signs of withdrawal
irritability and excessive high-pitched crying, tremor, frantic suckling, hyperactive reflexes
increased RR, increased stools, sneezing, yawning, vomiting and fever
incidence of diabetes mellitus
between 7-8%
incidence is expected to increase in the future
major public health issue